Trevi Therapeutics (TRVI) stock Forecast for 2022 – 2026

Trevi Therapeutics (TRVI) stock Forecast for 2022 – 2026

Last update: 05-29-2022, 6:04

Sector: Healthcare

The share price of Trevi Therapeutics, Inc. (TRVI) now

What analysts predict:: $8.67

52-week high/low: $3.731 / $0.46

50/200 Day Moving Average: $2.377 / $1.425

This figure corresponds to the average price over the previous 50/200 days. For Trevi Therapeutics stocks, the 50-day moving average is the support level today.

For Trevi Therapeutics stocks, the 200-day moving average is the support level today.

Are you interested in Trevi Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Trevi Therapeutics stock price in 2022, 2023, 2024, 2025, 2026. How much will one Trevi Therapeutics share be worth in 2022 - 2026?

When should I take profit in Trevi Therapeutics stock? When should I record a loss on Trevi Therapeutics stock? What are analysts' forecasts for Trevi Therapeutics stock? What is the future of Trevi Therapeutics stock?

We forecast Trevi Therapeutics stock performance using neural networks based on historical data on Trevi Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Trevi Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)

The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Trevi Therapeutics shares. This happens once a day.




Historical and forecast chart of Trevi Therapeutics stock

The chart below shows the historical price of Trevi Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Trevi Therapeutics stock price can be found in the table below.

Long-term forecasts by years.

Trevi Therapeutics daily forecast for a month

Date Target Pes. Opt. Vol., %
May 31 2.76 2.51 2.91 15.99
Jun 01 2.83 2.74 2.98 8.84
Jun 02 2.52 2.25 2.78 23.67
Jun 03 2.56 2.32 2.70 16.35
Jun 04 2.78 2.51 2.98 18.98
Jun 05 2.60 2.34 2.74 16.98
Jun 06 2.67 2.49 2.87 15.28
Jun 07 2.84 2.61 3.16 21.06
Jun 08 3.24 2.96 3.58 21.03
Jun 09 3.03 2.73 3.39 24.14
Jun 10 2.79 2.55 2.88 12.94
Jun 11 2.63 2.49 2.83 13.48
Jun 12 2.48 2.32 2.66 14.61
Jun 13 2.42 2.20 2.62 19.12
Jun 14 2.52 2.27 2.71 18.98
Jun 15 2.51 2.41 2.75 13.87
Jun 16 2.67 2.37 2.95 24.13
Jun 17 2.74 2.56 2.87 12.06
Jun 18 2.60 2.44 2.85 16.97
Jun 19 2.71 2.41 3.00 24.59
Jun 20 2.85 2.71 3.07 13.21
Jun 21 2.80 2.72 3.06 12.68
Jun 22 3.15 2.96 3.45 16.76
Jun 23 3.58 3.36 3.83 14.07
Jun 24 3.70 3.39 3.85 13.76
Jun 25 3.97 3.68 4.16 13.28
Jun 26 3.88 3.51 4.18 19.25
Jun 27 3.66 3.42 3.88 13.51
Jun 28 3.94 3.67 4.14 12.87
Jun 29 3.59 3.43 3.90 13.84

Trevi Therapeutics Daily Price Targets


Trevi Therapeutics Stock Forecast 05-31-2022.

Forecast target price for 05-31-2022: $2.76. Positive dynamics for Trevi Therapeutics shares will prevail with possible volatility of 13.785%.

Pessimistic target level: 2.51

Optimistic target level: 2.91


Trevi Therapeutics Stock Forecast 06-01-2022.

Forecast target price for 06-01-2022: $2.83. Positive dynamics for Trevi Therapeutics shares will prevail with possible volatility of 8.124%.

Pessimistic target level: 2.74

Optimistic target level: 2.98


Trevi Therapeutics Stock Forecast 06-02-2022.

Forecast target price for 06-02-2022: $2.52. Negative dynamics for Trevi Therapeutics shares will prevail with possible volatility of 19.140%.

Pessimistic target level: 2.25

Optimistic target level: 2.78


Trevi Therapeutics Stock Forecast 06-03-2022.

Forecast target price for 06-03-2022: $2.56. Positive dynamics for Trevi Therapeutics shares will prevail with possible volatility of 14.049%.

Pessimistic target level: 2.32

Optimistic target level: 2.70


Trevi Therapeutics Stock Forecast 06-04-2022.

Forecast target price for 06-04-2022: $2.78. Positive dynamics for Trevi Therapeutics shares will prevail with possible volatility of 15.951%.

Pessimistic target level: 2.51

Optimistic target level: 2.98


Trevi Therapeutics Stock Forecast 06-05-2022.

Forecast target price for 06-05-2022: $2.60. Negative dynamics for Trevi Therapeutics shares will prevail with possible volatility of 14.516%.

Pessimistic target level: 2.34

Optimistic target level: 2.74


TRVI (TRVI) Monthly Stock Prediction for 2022

Month Target Pes. Opt. Vol., %
Jun. 2.21 2.02 2.35 14.11
Jul. 2.76 2.26 3.19 29.33
Aug. 2.37 2.16 2.82 23.47
Sep. 2.32 2.11 2.52 16.05
Oct. 2.52 2.03 2.91 30.36
Nov. 2.61 2.29 2.95 22.32
Dec. 2.77 2.54 3.40 25.35

Trevi Therapeutics forecast for this year


Trevi Therapeutics Stock Prediction for Jun 2022

An downtrend is forecast for this month with an optimal target price of $2.2116. Pessimistic: $2.02. Optimistic: $2.35


Trevi Therapeutics Stock Prediction for Jul 2022

An uptrend is forecast for this month with an optimal target price of $2.76229. Pessimistic: $2.26. Optimistic: $3.19


Trevi Therapeutics Stock Prediction for Aug 2022

An downtrend is forecast for this month with an optimal target price of $2.37281. Pessimistic: $2.16. Optimistic: $2.82


Trevi Therapeutics Stock Prediction for Sep 2022

An downtrend is forecast for this month with an optimal target price of $2.32298. Pessimistic: $2.11. Optimistic: $2.52


Trevi Therapeutics Stock Prediction for Oct 2022

An uptrend is forecast for this month with an optimal target price of $2.51811. Pessimistic: $2.03. Optimistic: $2.91


Trevi Therapeutics Stock Prediction for Nov 2022

An uptrend is forecast for this month with an optimal target price of $2.60876. Pessimistic: $2.29. Optimistic: $2.95


Trevi Therapeutics Stock Prediction for Dec 2022

An uptrend is forecast for this month with an optimal target price of $2.76528. Pessimistic: $2.54. Optimistic: $3.40




Trevi Therapeutics (TRVI) Monthly Stock Prediction for 2023

Month Target Pes. Opt. Vol., %
Jan 2.81 2.58 3.43 24.80
Feb 3.08 2.58 3.40 24.23
Mar 3.87 3.20 4.42 27.61
Apr 4.00 3.68 4.48 17.95
May 4.23 3.45 4.92 29.87
Jun 4.57 4.20 5.54 24.24
Jul 4.27 3.37 5.02 32.88
Aug 4.28 3.64 4.76 23.49
Sep 4.77 4.05 5.13 20.93
Oct 5.17 4.60 6.05 24.08
Nov 6.50 5.14 7.19 28.51
Dec 7.73 6.92 8.43 17.89

Trevi Therapeutics (TRVI) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jan 5.50 4.37 5.95 26.64
Feb 6.31 4.84 7.66 36.85
Mar 5.40 4.38 5.84 24.98
Apr 4.97 4.18 5.46 23.48
May 4.74 3.68 5.78 36.42
Jun 5.87 5.02 6.41 21.68
Jul 5.13 4.30 6.25 31.26
Aug 6.08 5.17 7.14 27.60
Sep 4.88 4.34 5.80 25.23
Oct 3.46 2.83 4.28 33.95
Nov 3.94 3.70 4.38 15.62
Dec 4.43 3.55 4.76 25.40



Trevi Therapeutics (TRVI) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 5.36 4.20 6.02 30.19
Feb 5.75 4.75 6.92 31.40
Mar 6.39 5.28 7.92 33.39
Apr 7.11 5.81 8.05 27.83
May 6.75 5.13 7.16 28.30
Jun 8.64 6.74 10.35 34.81
Jul 7.39 6.44 9.01 28.55
Aug 8.52 7.73 9.80 21.13
Sep 7.24 6.66 8.31 19.88
Oct 7.74 5.98 8.30 27.99
Nov 8.67 7.66 10.52 27.21
Dec 8.47 7.78 9.68 19.67

Trevi Therapeutics (TRVI) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 9.76 7.56 11.40 33.65
Feb 9.41 7.66 11.50 33.39
Mar 12.03 11.28 13.62 17.23
Apr 14.81 11.39 17.13 33.48
May 17.26 14.93 20.11 25.75
Jun 14.83 13.76 16.96 18.88
Jul 16.87 15.51 19.91 22.12
Aug 15.30 11.91 17.69 32.70
Sep 12.73 10.13 13.92 27.17
Oct 13.95 12.61 15.80 20.14
Nov 11.82 9.62 13.45 28.47
Dec 9.27 8.43 11.18 24.61

Trevi Therapeutics information and performance

Trevi Therapeutics Inc. is a clinical biopharmaceutical company focused on the development and commercialization of Nalbuphine ER for the treatment of neurologically mediated conditions. The company is developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LD), in patients with Parkinson’s disease. The company is conducting phase 2b/3 clinical trials for nalbuphine ER. The company has also initiated a phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics, and antipruritic effect of nalbuphine ER in this population. The Company’s nalbuphine development programs for ER include the Chronic Pruritus Program, the Nodular Pruritus Program, the Chronic Liver Disease Pruritus Program, and the Uremic Pruritus Program.

Trevi Therapeutics Address

195 CHURCH STREET, 14TH FLOOR, NEW HAVEN, CT, US

Market Capitalization: 87 043 000 $

Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.

EBITDA: -23 079 000 $

EBITDA is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: None

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: N/A

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -1.281

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A

Quarterly Revenue Growth YOY: N/A

Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: -

Enterprise Value (EV) /Revenue

EV To EBITDA: 0.0232

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 38685600

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A

Percent Insiders: N/A

Percent Institutions: N/A




Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.